Weekly Research Analysts’ Ratings Updates for Vertex Pharmaceuticals (VRTX)

A number of research firms have changed their ratings and price targets for Vertex Pharmaceuticals (NASDAQ: VRTX):

• 9/11/2026 – Vertex Pharmaceuticals had its “overweight” rating reaffirmed by JPMorgan Chase & Co.. They now have a $560.00 price target on the stock, up from $515.00.
• 9/10/2026 – Vertex Pharmaceuticals was upgraded by Weiss Ratings from “buy (b-)” to “buy (b)”.
• 9/1/2026 – Vertex Pharmaceuticals is now covered by Morgan Stanley. They set an “overweight” rating and a $665.00 price target on the stock.
• 9/1/2026 – Vertex Pharmaceuticals was given a new $653.00 price target by The Goldman Sachs Group, Inc..
• 8/25/2026 – Vertex Pharmaceuticals was downgraded by Weiss Ratings from “buy (b)” to “buy (b-)”.
• 8/5/2026 – Vertex Pharmaceuticals was upgraded by Weiss Ratings from “buy (b-)” to “buy (b)”.
• 8/5/2026 – Vertex Pharmaceuticals had its price target raised by Truist Financial Corporation from $560.00 to $565.00. They now have a “buy” rating on the stock.
• 8/5/2026 – Vertex Pharmaceuticals had its price target raised by Barclays PLC from $615.00 to $617.00. They now have an “overweight” rating on the stock.
• 8/4/2026 – Vertex Pharmaceuticals had its price target raised by TD Cowen from $525.00 to $550.00. They now have a “buy” rating on the stock.
• 8/4/2026 – Vertex Pharmaceuticals was given a new $500.00 price target by Stifel Nicolaus.
• 8/4/2026 – Vertex Pharmaceuticals had its price target raised by Canaccord Genuity Group Inc. from $436.00 to $442.00. They now have a “hold” rating on the stock.
• 8/4/2026 – Vertex Pharmaceuticals had its price target raised by Cantor Fitzgerald from $590.00 to $595.00. They now have an “overweight” rating on the stock.
• 7/29/2026 – Vertex Pharmaceuticals was upgraded by Sanford C. Bernstein to “strong-buy”.

Insider Transactions at Vertex Pharmaceuticals

In related news, EVP Duncan McKechnie sold 1,541 shares of the company’s stock in a transaction dated Thursday, July 2nd. The stock was sold at an average price of $519.00, for a total transaction of $799,779.00. Following the sale, the executive vice president owned 11,001 shares in the company, valued at $5,709,519. This represents a 12.29% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CMO Carmen Bozic sold 596 shares of the firm’s stock in a transaction that occurred on Friday, June 26th. The stock was sold at an average price of $482.50, for a total value of $287,570.00. Following the sale, the chief marketing officer directly owned 15,337 shares of the company’s stock, valued at $7,400,102.50. This represents a 3.74% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last ninety days, insiders sold 3,637 shares of company stock valued at $1,874,834. Corporate insiders own 0.20% of the company’s stock.

Vertex Pharmaceuticals Incorporated is a global biotechnology company focused on developing and commercializing medicines for serious diseases. Founded in 1989 and headquartered in Boston, Massachusetts, the company combines research in human genetics with drug discovery and development.

Vertex is best known for its cystic fibrosis portfolio, which includes CFTR modulator therapies such as Kalydeco, Orkambi, Symdeko and the combination marketed as Trikafta in the United States and Kaftrio in other markets.